Close

Pre-Open Stock Movers 05/04: (BLRX) (UFS) (TBBL) Higher; (SDC) (IRBT) (MAXR) Lower (more...)

May 4, 2021 9:20 AM EDT

Pre-Open Stock Movers:

BioLineRx Ltd. (NASDAQ: BLRX) 54% HIGHER; announced positive top-line results from the Company's GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, in combination with granulocyte colony stimulating factor (G-CSF, the standard of care in this indication), for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients.

Domtar (NYSE: UFS) 17% HIGHER; Paper Excellence is exploring a deal to acquire Domtar (NYSE: UFS), according to Bloomberg, citing people familiar with the matter.
The Bancorp Inc. (NASDAQ: TBBK) 12% HIGHER; will replace R1 RCM in the S&P SmallCap 600
SmileDirectClub (NYSE: SDC) 10% LOWER; Expects Revenue Impact From Cyber-attack

iRobot Corp. (NASDAQ: IRBT) 9.5% LOWER; reported Q1 EPS of $0.41, $0.32 better than the analyst estimate of $0.09. Revenue for the quarter came in at $303.3 million versus the consensus estimate of $264.05 million. iRobot Corp. sees FY2021 EPS of $3.00-$3.25, versus the consensus of $3.22. iRobot Corp. sees FY2021 revenue of $1.67-1.71 billion, versus the consensus of $1.65 billion.

Renewable Energy Group (NASDAQ: REGI) 8.8% HIGHER; reported Q1 EPS of $0.88, $0.70 better than the analyst estimate of $0.18. Revenue for the quarter came in at $540 million versus the consensus estimate of $535.26 million.

Maxar Technologies Ltd. (NYSE: MAXR) 7% LOWER; reported Q1 EPS of ($1.30), $2.36 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $392 million versus the consensus estimate of $560.3 million.

Chegg (NYSE: CHGG) 6% HIGHER; reported Q1 EPS of $0.28, $0.02 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $198.4 million versus the consensus estimate of $184.59 million. Chegg sees Q2 2021 revenue of $188-190 million, versus the consensus of $192.31 million. Chegg sees FY2021 revenue of $790-800 million, versus the consensus of $790.46 million.

ProQR Therapeutics N.V. (Nasdaq: PRQR) 5.5% HIGHER; RTW Investments, LP (RTW), a global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors, and ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Yarrow Biotechnology, Inc. (Yarrow) , a company newly created by RTW, has in-licensed exclusive rights to ProQRs antisense oligonucleotide technology (ASO) to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. Yarrow is focused on developing ASO-based therapeutics for disorders with high unmet need.

ELEVATE CREDIT, INC. (NYSE: ELVT) 4.9% HIGHER; reported Q1 EPS of $0.34, $0.22 better than the analyst estimate of $0.12. Revenue for the quarter came in at $89.7 million versus the consensus estimate of $91.48 million.

Ferrari N.V. (NYSE: RACE) 4% LOWER; reported Q1 EPS of EUR1.11, versus EUR0.90 reported last year. Revenue for the quarter came in at EUR1.01 billion, versus EUR932 million reported last year.

The Mosaic Company (NYSE: MOS) 3.7% LOWER; reported Q1 EPS of $0.57, $0.05 better than the analyst estimate of $0.52. Revenue for the quarter came in at $2.3 billion versus the consensus estimate of $2.25 billion.

Varonis Systems (NASDAQ: VRNS) 2.9% LOWER; reported Q1 EPS of ($0.08), $0.05 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $74.79 million versus the consensus estimate of $68.9 million. Varonis Systems sees Q2 2021 EPS of ($0.04)-($0.03), versus the consensus of ($0.04). Varonis Systems sees Q2 2021 revenue of $82.5-84 million, versus the consensus of $82.51 million. Varonis Systems sees FY2021 EPS of ($0.01)-$0.02, versus the consensus of $0.00. Varonis Systems sees FY2021 revenue of $365-370 million, versus the consensus of $364.82 million.

Leggett & Platt (NYSE: LEG) 1.7% HIGHER; reported Q1 EPS of $0.64, $0.22 better than the analyst estimate of $0.42. Revenue for the quarter came in at $1.15 billion versus the consensus estimate of $1.14 billion. Leggett & Platt sees FY2021 EPS of $2.55-$2.75, versus the consensus of $2.47. Leggett & Platt sees FY2021 revenue of $4.8-5 billion, versus the consensus of $4.79 billion.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Standard & Poor's, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers